DGIdb - PELAREOREP Drug Record

PELAREOREP chembl:CHEMBL3545069 Antineoplastic

Alternate Names:

REOLYSIN
PO-BB0209
PELAREOREP
PO-BB-0209

Drug Info:

FDA Approval	not approved
Drug Class	reovirus
Drug Indications	antineoplastic agent
Pharmaceutical Developer	Oncolytics Biotech
Source Reported Drug Name(s)	Reolysin
Drug Class	Ras Inhibitor

(1 More Sources)

Publications:

Maitra et al., 2014, Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan., Oncotarget
Mahalingam et al., 2015, The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer., BMC Cancer

PELAREOREP HRAS

Interaction Score: 0.62

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name Reolysin

Novel drug target Novel Target

PMIDs:
None found

Sources:
TdgClinicalTrial
PELAREOREP KRAS

Interaction Score: 0.62

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

combination therapy Reolysin + Gemcitabine

Indication/Tumor Type pancreatic cancer

Response Type sensitive

PMIDs:
24798549 26156229

Sources:
JAX-CKB CancerCommons
PELAREOREP NRAS

Interaction Score: 0.44

Interaction Types & Directionality:

n/a

Interaction Info:

Novel drug target Novel Target

Trial Name Reolysin

PMIDs:
None found

Sources:
TdgClinicalTrial

CancerCommons: REOLYSIN
- Version: 25-July-2013
Alternate Names:

Reolysin Drug Trade Name

Reolysin Drug Development Name

Drug Info:

Drug Class Ras Inhibitor

Source Reported Drug Name(s) Reolysin

Pharmaceutical Developer Oncolytics Biotech

Publications:
TdgClinicalTrial: REOLYSIN
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class reovirus

FDA Approval not approved

Publications:

JAX-CKB: Reolysin

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Mahalingam et al., 2015, The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer., BMC Cancer

Maitra et al., 2014, Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan., Oncotarget

TALC: REOLYSIN
- Version: 12-May-2016
Alternate Names:

REOLYSIN Primary Drug Name

REOLYSIN Drug Trade Name

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL3545069
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

PELAREOREP Drug Record

PELAREOREP chembl:CHEMBL3545069 Antineoplastic

Alternate Names:

Drug Info:

Publications:

PELAREOREP HRAS

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name Reolysin

Novel drug target Novel Target

PMIDs:
None found

Sources:
TdgClinicalTrial

PELAREOREP KRAS

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

combination therapy Reolysin + Gemcitabine

Indication/Tumor Type pancreatic cancer

Response Type sensitive

PMIDs:
24798549 26156229

Sources:
JAX-CKB CancerCommons

PELAREOREP NRAS

Interaction Types & Directionality:

n/a

Interaction Info:

Novel drug target Novel Target

Trial Name Reolysin

PMIDs:
None found

Sources:
TdgClinicalTrial

CancerCommons: REOLYSIN

Alternate Names:

Reolysin Drug Trade Name

Reolysin Drug Development Name

Drug Info:

Drug Class Ras Inhibitor

Source Reported Drug Name(s) Reolysin

Pharmaceutical Developer Oncolytics Biotech

Publications:

TdgClinicalTrial: REOLYSIN

Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class reovirus

FDA Approval not approved

Publications:

JAX-CKB: Reolysin

Alternate Names:

Drug Info:

TALC: REOLYSIN

Alternate Names:

REOLYSIN Primary Drug Name

REOLYSIN Drug Trade Name

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL3545069

Alternate Names:

Drug Info:

Publications:

combination therapy	Reolysin + Gemcitabine
Indication/Tumor Type	pancreatic cancer
Response Type	sensitive

PELAREOREP Drug Record

PELAREOREP chembl:CHEMBL3545069 Antineoplastic

Alternate Names:

Drug Info:

Publications:

PELAREOREP HRAS

Interaction Types & Directionality: n/a

Interaction Info: Trial Name Reolysin Novel drug target Novel Target

PMIDs: None found

Sources: TdgClinicalTrial

PELAREOREP KRAS

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: combination therapy Reolysin + Gemcitabine Indication/Tumor Type pancreatic cancer Response Type sensitive

PMIDs: 24798549 26156229

Sources: JAX-CKB CancerCommons

PELAREOREP NRAS

Interaction Types & Directionality: n/a

Interaction Info: Novel drug target Novel Target Trial Name Reolysin

PMIDs: None found

Sources: TdgClinicalTrial

CancerCommons: REOLYSIN

Alternate Names: Reolysin Drug Trade Name Reolysin Drug Development Name

Drug Info: Drug Class Ras Inhibitor Source Reported Drug Name(s) Reolysin Pharmaceutical Developer Oncolytics Biotech

Publications:

TdgClinicalTrial: REOLYSIN

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class reovirus FDA Approval not approved

Publications:

JAX-CKB: Reolysin

Alternate Names:

Drug Info:

TALC: REOLYSIN

Alternate Names: REOLYSIN Primary Drug Name REOLYSIN Drug Trade Name

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL3545069

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name Reolysin

Novel drug target Novel Target

PMIDs:
None found

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

combination therapy Reolysin + Gemcitabine

Indication/Tumor Type pancreatic cancer

Response Type sensitive

PMIDs:
24798549 26156229

Sources:
JAX-CKB CancerCommons

Interaction Types & Directionality:

n/a

Interaction Info:

Novel drug target Novel Target

Trial Name Reolysin

PMIDs:
None found

Sources:
TdgClinicalTrial

Alternate Names:

Reolysin Drug Trade Name

Reolysin Drug Development Name

Drug Info:

Drug Class Ras Inhibitor

Source Reported Drug Name(s) Reolysin

Pharmaceutical Developer Oncolytics Biotech

Drug Info:

Drug Indications antineoplastic agent

Drug Class reovirus

FDA Approval not approved

Alternate Names:

REOLYSIN Primary Drug Name

REOLYSIN Drug Trade Name